After Record Breaking Demand for Injectable Drugs, BD Expands Spain to $ 200 Million Plant in Zaragoza – Endpoints News



After the surge in vaccinations over the past year, New Jersey-based BD is doubling demand for injectable drugs and relying on its Spanish operations.

BD will begin construction of a $ 200 million manufacturing facility in Zaragoza that will make drug delivery devices for vaccines and biologics, the company announced this week. This facility will be the company’s fourth in the country and will be part of the $ 1.2 billion supply chain investment the company has committed to over the next four years.

Prefillable syringe technology and an advanced drug delivery and manufacturing strategy are two key elements of the company’s 2025 growth strategy announced in December 2020. The plant will supply syringes to the European market and expand capacity to adequately respond to future major vaccination campaigns. like the current pandemic.

The company has deployed more than 1 billion injection devices to help the pandemic in at least 10 countries, BD said.

Currently, the other three locations in San Agustín de Guadalix, Fraga and Almaraz produce 10 billion medical devices each year, and the Fraga plant is a key location for Covid-19 vaccine injection equipment. In a statement, General Manager Lourdes López said:

Following BD’s announcement in December 2020 that it would build a new plant in Europe, a detailed location search resulted in Zaragoza, Aragon being selected due to the optimal conditions of the region, the synergies that could be achieved with the BD Fraga plant . and the results and excellent performance of the facilities currently in existence in Spain.

The 86,000 square meter plant will initially employ 150 people. By 2030, it should have a size of 323,000 square meters and employ up to 600 people. The other three facilities in Spain currently employ 1,500 people.

In November 2020, BD a statement stated that they were “short of supply” in certain product categories and published guidelines for customers and partners encouraging them not to order oversupplies or to stock equipment. The surge in vaccination against Covid-19 combined with the increase in flu vaccinations led to a steady increase in demand.

Just two weeks ago, the company decided to outsource its diabetes care business, which had built a portfolio of insulin injection devices for years. This move will create a publicly traded company that will go live in 2022 and focus on leveraging its insulin delivery. On May 13, BD also announced testing of its first home HPV screening device, aimed at women who do not have access to routine testing.

The company announced that revenue for the second quarter was $ 4.9 billion, up 15% year over year.



Comments are closed.